Joe Jimenez (Steffen Schmidt/Keystone via AP,file)
November 7, 2024 07:03 AM EST
Startups
Deals
China

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Kyle LaHucik

Senior Reporter

Joe Jimenez’s Adi­tum Bio, an in­vest­ment firm that builds com­pa­nies around in-li­censed as­sets, is go­ing af­ter one of the hottest new ar­eas for its lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times